Showing results (171-180 of 379) with videos related to

Sort By:
Pageof 38
Kidney International Reports|July 31, 2024
The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A NephropathyDana Kim, Jicheng Lv, Michelle Hladunewich, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 18, 2015
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled TrialGreg Fulcher, David R Matthews, Vlado Perkovic, et al.
Diabetes, Obesity & Metabolism|January 9, 2025
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trialAmanda Siriwardana, Luke Buizen, Min Jun, et al.
Kidney International Reports|February 22, 2021
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin ReceptorMegumi Oshima, Akinori Hara, Tadashi Toyama, et al.
Stroke|April 20, 2021
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-AnalysisZien Zhou, Meg J Jardine, Qiang Li, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 24, 2020
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Diabetes Care|December 4, 2014
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetesBruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
Diabetes, Obesity & Metabolism|February 15, 2022
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trialJennifer Y Barraclough, Jie Yu, Gemma A Figtree, et al.
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.
Pageof 38